1 Table of Contents: “... Foot Skin Reaction -- MEK Inhibitors (trametinib) -- Anti-PD1 (ipilimumab) -- Tyrosine Kinase...”

2 Table of Contents: “... advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung...”

3 Table of Contents: “... and Metastatic Nasopharyngeal Carcinoma -- Beyond PD-1/PD-L1 Immune Checkpoint Inhibitors: Other Targets...”

4 Table of Contents: “... cell pathways -- PD1 and PD1l immune checkpoint inhibitors -- The Role of the JAK/STAT Signaling...”

5 Table of Contents: “... Considerations with EGFR inhibitors in NSCLC -- Chapter 4. Nursing Considerations with ALK and ROS1 inhibitors...”

6 Table of Contents: “...Introduction -- Molecular and cellular functions of CTLA-4 pathway -- Roles of PD-1/PD-L1 pathway...”

7 Table of Contents: “... of selenium, iron, copper and zinc in on/off Parkinson’s patients on L-dopa therapy -- Metal specificity...”

8 Table of Contents: “...-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies -- Treatment of melanoma with agonist immune co...”

9 Table of Contents: “...Antibody-drug conjugates -- Tumor-Infiltrating Lymphocytes as a Surrogate Biomarker for PD-L1...”

10 Table of Contents: “... beyond PD-1/PD-L1 in head and neck cancer, Christophe Le Tourneau -- Analytic methods to understand head...”

11 Table of Contents: “... we treat the patients failed to PD-1/PD-L1 inhibitors? -- 23. Biomarkers for Immune checkpoint...”

12 Table of Contents: “... and Con: the rotenone model of Parkinson’s disease (PD) -- Proposed animal model of severe Parkinson’s...”